Diabetes patients on incretin mimetics do not have higher cancer risk

06/5/2013 | Healio

A study presented at Digestive Disease Week revealed insulin-stimulating treatments including incretin mimetics were not associated with an increased risk of pancreatic adenocarcinoma in diabetes patients. However, researchers said longer-term studies are needed to further assess the drugs' effect, as incretin mimetics have only been available for less than 10 years whereas pancreatic cancer develops over 18 years.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX